- Home
- MNOV vs DOUG Comparison
MNOV vs DOUG Comparison
Compare MNOV & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MNOV | DOUG |
|---|---|---|
| Founded | 2000 | 1911 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.8M | 145.4M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MNOV | DOUG |
|---|---|---|
| Price | $1.42 | $1.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.25 | N/A |
| AVG Volume (30 Days) | ★ 786.3K | 516.8K |
| Earning Date | 11-11-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 118.68 |
| EPS | ★ N/A | N/A |
| Revenue | $2,360,807.00 | ★ $955,578,000.00 |
| Revenue This Year | $78.20 | $0.59 |
| Revenue Next Year | N/A | $7.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 194.15 | N/A |
| 52 Week Low | $1.17 | $1.42 |
| 52 Week High | $3.90 | $3.03 |
Technical Indicators
Market Signals| Indicator | MNOV | DOUG |
|---|---|---|
| Relative Strength Index (RSI) | 36.26 | 35.31 |
| Support Level | $1.29 | N/A |
| Resistance Level | $1.48 | $1.84 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 1.55 | 23.68 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.